That the House of Representatives ban all advertising by pharmaceutical companies and of any pharmaceuticals on any New Zealand media including television, radio, newspapers, magazines, billboards and ...

In the CLEAR SYNERGY trial, routine spironolactone after myocardial infarction did not reduce cardiovascular AEs in patients ...

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...

The use of SGLT2 inhibitors vs GLP-1 receptor agonists was linked to a reduced risk for ULT and colchicine initiation among ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a ...

New research found that the medication spironolactone, often prescribed for hypertension (high blood pressure), may reduce the risk of heart failure in people recovering from a heart attack.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Colchicine, a medication with well-documented anti-inflammatory action and with an impact on reducing cardiovascular outcomes, may influence reducing FAI (Fat Attenuation index) assessed by coronary ...

The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not ...

The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not ...